Angion Biomedica Corp.
ANGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.17 | 0.05 |
| FCF Yield | -304.47% | 0.00% | -157.46% | -64.74% |
| EV / EBITDA | -0.01 | 0.00 | 1.11 | 0.04 |
| Quality | ||||
| ROIC | -256.24% | 0.00% | -92.00% | -44.95% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 98.47% |
| Cash Conversion Ratio | 1.16 | 0.93 | 0.99 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -7.21% | 167.03% | -10.59% |
| Free Cash Flow Growth | -13.42% | 14.67% | 27.60% | -131.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.00 | 2.33 | 1.51 |
| Interest Coverage | 98.87 | 0.00 | -37.81 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.30 |
| Cash Conversion Cycle | 0.00 | 0.00 | 48.38 | -2,748.60 |